News archive
Showing 697 results
December 2010
-
Media Release
Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
- In a clinical trial, Amturnide demonstrated significantly greater reductions in blood pressure compared to all dual combinations of its components- Amturnide combines the only approved direct renin… -
Media Release
Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
-
Media Release
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the… -
Media Release
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
November 2010
-
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
Elimination of 1,400 General Medicines field force positions effective January 1 to align organization with changes in portfolio and evolving healthcare market New organizational alignment creates… -
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
“Stand Together for AD: Strength and Support for Alzheimer’s” at AlzheimersDisease.com empowers caregivers with new resources and tools to help navigate challenges of caring for a loved one with… -
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
October 2010
-
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
- Review of data from more than 12,000 people in Cystic Fibrosis Foundation's Patient Registry shows 21% mortality reduction in patients treated with TOBI- TOBI is a widely used inhaled antibiotic… -
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
September 2010
-
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Gilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this diseaseGilenya showed superior efficacy by reducing relapses by 52% at… -
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression